311 related articles for article (PubMed ID: 26033735)
21. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Leonard SN; Rybak MJ
J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
[TBL] [Abstract][Full Text] [Related]
22. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
Farrell DJ; Flamm RK; Sader HS; Jones RN
Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
[TBL] [Abstract][Full Text] [Related]
23. Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections.
Thangamani S; Younis W; Seleem MN
Sci Rep; 2015 Jun; 5():11596. PubMed ID: 26111644
[TBL] [Abstract][Full Text] [Related]
24. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
[TBL] [Abstract][Full Text] [Related]
25. Activity of Different Antistaphylococcal Therapies, Alone or Combined, in a Rat Model of Methicillin-Resistant Staphylococcus epidermidis Osteitis without Implant.
Albac S; Labrousse D; Hayez D; Anzala N; Bonnot D; Chavanet P; Aslangul E; Croisier D
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31740562
[TBL] [Abstract][Full Text] [Related]
26. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
Salem AH; Zhanel GG; Ibrahim SA; Noreddin AM
Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):437-43. PubMed ID: 24341387
[TBL] [Abstract][Full Text] [Related]
27. In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus.
Oh SH; Park HS; Lee JH; Baek SY; Chae SE; Oh K; Cho YL; Kwak JH
Molecules; 2017 Nov; 22(12):. PubMed ID: 29186032
[No Abstract] [Full Text] [Related]
28. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
Escaich S; Prouvensier L; Saccomani M; Durant L; Oxoby M; Gerusz V; Moreau F; Vongsouthi V; Maher K; Morrissey I; Soulama-Mouze C
Antimicrob Agents Chemother; 2011 Oct; 55(10):4692-7. PubMed ID: 21825292
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus.
Park YS; Shin WS; Kim SK
J Antimicrob Chemother; 2008 Jan; 61(1):163-8. PubMed ID: 17967852
[TBL] [Abstract][Full Text] [Related]
30. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
Mirza HC; Sancak B; Gür D
Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
Appleman MD; Citron DM
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335
[TBL] [Abstract][Full Text] [Related]
32. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
[TBL] [Abstract][Full Text] [Related]
33. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
LaPlante KL; Rybak MJ
Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
[TBL] [Abstract][Full Text] [Related]
34. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Akins RL; Rybak MJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):454-9. PubMed ID: 11158740
[TBL] [Abstract][Full Text] [Related]
35. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.
Bowker KE; Noel AR; MacGowan AP
J Antimicrob Chemother; 2009 Nov; 64(5):1044-51. PubMed ID: 19759041
[TBL] [Abstract][Full Text] [Related]
36. Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
Bi F; Song D; Qin Y; Liu X; Teng Y; Zhang N; Zhang P; Zhang N; Ma S
Bioorg Med Chem; 2019 Jul; 27(14):3179-3193. PubMed ID: 31200986
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
38. The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant
Indiani C; Sauve K; Raz A; Abdelhady W; Xiong YQ; Cassino C; Bayer AS; Schuch R
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670427
[TBL] [Abstract][Full Text] [Related]
39. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.
Mendes RE; Sader HS; Flamm RK; Farrell DJ; Jones RN
Antimicrob Agents Chemother; 2015 Mar; 59(3):1811-4. PubMed ID: 25561335
[TBL] [Abstract][Full Text] [Related]
40. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Tsuji BT; Rybak MJ
Antimicrob Agents Chemother; 2005 Jul; 49(7):2735-45. PubMed ID: 15980344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
